Research

The study could suggest ways to promote the transport of phospholipids and cholesterol out of macrophages, immune system cells that play key roles in all stages of atherosclerosis development.
January 19, 2023

Study points to new ways to prevent, treat heart disease

Vanderbilt researchers have confirmed the existence of an alternative pathway to atherosclerosis, a finding that may lead to new ways to prevent and treat cardiovascular disease.

January 19, 2023

Is drinking tea good for your gut?

Microbiome profiling of older Chinese adults showed that tea drinking changed the diversity and abundance of some bacteria in men but not women — effects that may contribute to a reduced risk of hypertension.

January 19, 2023

Low potassium injures kidney

Vanderbilt researchers have discovered that low dietary potassium causes direct kidney injury, suggesting potential new targets for treating chronic kidney disease.

Jeffrey Rathmell, PhD, left, and Kelsey Voss, PhD, led a multidisciplinary team that identified iron metabolism in T cells as a potential target for treating lupus.
January 13, 2023

Study identifies potential new approach for treating lupus

A Vanderbilt study found that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus — the most common form of the chronic autoimmune disease lupus.

January 12, 2023

Antibody “fingerprinting” method potential advance to slow spread of dengue

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

Alexander Bick, MD, PhD, and colleagues are studying inflammation at the single-cell level in the rare disease RUNX1-FPD.
January 12, 2023

Chan Zuckerberg Initiative grant supports single-cell study of rare inherited disease

A multidisciplinary team led by Vanderbilt University Medical Center investigator Alexander Bick, MD, PhD, has been awarded a $2 million, four-year grant to study inflammation at the single-cell level in the rare disease RUNX1-FPD.